Noxap (Nitric Oxide)

Noxap, a nitric oxide donor, is employed in clinical settings that require pulmonary vasodilation or vascular imaging.

• Persistent pulmonary hypertension of the newborn (PPHN): improves oxygenation by lowering pulmonary vascular resistance.
• Acute respiratory distress syndrome (ARDS): provides selective pulmonary vasodilation to enhance gas exchange.
• Pulmonary hypertension during cardiac surgery: reduces right‑ventricular afterload and improves intra‑operative hemodynamics.
• Vascular imaging: acts as a contrast agent to delineate pulmonary vessels during functional imaging studies.

• Inhaled nitric oxide diffuses into pulmonary smooth‑muscle cells where it activates soluble guanylate cyclase, increasing cyclic GMP levels. Elevated cGMP triggers relaxation of vascular smooth muscle, producing selective pulmonary vasodilation without systemic effects. The rapid onset and short half‑life allow precise titration of pulmonary blood flow and improve ventilation‑perfusion matching.

Adverse reactions may occur with inhaled nitric oxide therapy.

Common Side Effects

• Hypotension: transient drop in systemic blood pressure.
• Headache: mild to moderate intensity.
• Dizziness or light‑headedness.
• Flushing of the skin.
• Nausea or mild gastrointestinal discomfort.
• Cough or throat irritation.

Serious or Rare Side Effects

• Methemoglobinemia: elevated methemoglobin levels impair oxygen delivery.
• Rebound pulmonary hypertension on abrupt discontinuation.
• Severe hypotension requiring intervention.
• Bleeding complications, especially when combined with anticoagulants.
• Infection risk if delivery system becomes contaminated.
• Pulmonary edema in susceptible patients.

Careful monitoring and specific precautions are recommended when using Noxap.

• Blood pressure monitoring: observe for hypotension and adjust therapy as needed.
• Methemoglobin assessment: regularly measure levels to detect methemoglobinemia.
• Controlled environment: administer only in facilities equipped for inhaled gas delivery and scavenging.
• Contraindications: avoid in patients with severe anemia or known hypersensitivity to nitric oxide.
• Caution with phosphodiesterase inhibitors: increased risk of profound hypotension.
• Store at ambient temperature: keep container sealed, protect from moisture and direct sunlight.

Nitric oxide can interact with several drug classes, requiring attention to avoid adverse events.

Major Interactions (Avoid)

• Phosphodiesterase‑5 inhibitors (e.g., sildenafil): may cause severe systemic hypotension.
• Inhaled anesthetics (e.g., nitrous oxide): additive vasodilatory effect increases hypotension risk.
• Systemic vasodilators (e.g., nitroglycerin): can potentiate blood pressure lowering.

Moderate Interactions (Monitor Closely)

• Anticoagulants: heightened bleeding tendency.
• Hemoglobin‑modifying agents: may exacerbate methemoglobinemia.
• Other nitric‑oxide donors: cumulative exposure can increase toxicity.
• Sulfonamide antibiotics: potential to raise methemoglobin levels.
• Bronchodilators: may alter distribution of inhaled gas and affect efficacy.